Rheumatology

Article	Citations
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	116
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?	86
Enhancing Gout Diagnosis with Deep Learning in Dual-energy Computed Tomography: A Retrospective Analysis of Crystal and Artifact Differentiation	81
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis	78
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	63
Boxer’s shape, an unusual finding in nailfold capillaroscopy	60
Giant cell arteritis of the prostate	58
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?	56
Clinical and serological resolution of pembrolizumab associated Sjögren’s syndrome: long-term follow-up	55
P174 Identifying patterns of fatigue across flares in patients with axial spondyloarthritis	54
P038 Let’s look at coxitis features in enthesitis-related arthritis population	54
E046 Lytic lesions; metastatic disease or gout?	52
P173 The positive utility of PSAID-12 score in remote monitoring and the impact of gender and treatment on patient reported outcomes in psoriatic arthritis	52
P073 Functional investigation of Osteoarthritis-associated non-coding variants using CRISPR/Cas9-mediated perturbation of active enhancer regions	49
P004 Empowering the reproductive choices of patients with rheumatic disease: using the BSR 2022 pregnancy guidelines audit tool to evaluate pre-conception medication advice	48
Editor’s Acknowledgement	47
P032 Methotrexate and hepatic tolerance in Juvenile Idiopathic Arthritis	47
P025 Risk assessment of covid 19 in patients with Juvenile Idiopathic Arthritis	47
Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis–associated interstitial lung disease	46
P031 Adherence with Methotrexate in Tunisian Juvenile Idiopathic Arthritis Patients	46
P261 Early and accurate diagnosis of patients with axial spondyloarthritis using machine learning: a predictive analysis from electronic health records in the United Kingdom	45
P185 Patients' and clinicians' perspectives on the clinical utility of the Rheumatoid Arthritis Foot Disease Activity Index	42
P077 Developing a better explanation of osteoarthritis: results from a conjoint analysis of patient preferences	42
Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies	42
OA04 COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a national cohort	42

P083 Undergraduate rheumatology teaching in the UK: a survey of teachers	41
P143 Frailty is associated with inflammation, impaired glucose metabolism and reduced bone mineral density after adjustment for fat mass index: a UK biobank study	41
P179 A feasibility randomised controlled trial of a fibromyalgia self-management programme in a community setting with a nested qualitative study	41
P131 Adult coeliac disease and bone mineral density at the femoral neck, total hip and lumbar spine: an age- and sex-matched case-control study	39
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	38
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	38
Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series	37
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	37
Comment on: Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease	36
Flare of multicentric reticulohistiocytosis in pregnancy	36
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus	36
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	36
Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behçet’s disease versus the general population	36
Incidence and course of COVID-19 hospitalizations among patients with familial Mediterranean fever	35
P011 Rituximab and COVID-19 vaccines; are they fit for purpose?	34
26 Kawasaki’s disease vs systemic juvenile idiopathic arthritis, a diagnostic dilemma	34
54 Kawasaki disease: experience in a general paediatric department of the CHU de Annaba Algeria	34
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	33
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study	33
Haematologic malignancy-associated mucocutaneous paraneoplastic syndrome	32
The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study	32
Corrigendum to: Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study	32
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis—caution is key in interpreting retrospective data: Reply	32
P047 Musculoskeletal symptoms as first clinical presentation of juvenile-onset systemic lupus erythematosus: Experience from a military internal medicine department	31
Extracorporeal membrane oxygenation for life-threatening ANCA-associated vasculitis with pulmonary haemorrhage	31
Lymphocyte subset phenotyping for the prediction of progression to inflammatory arthritis in anti-citrullinated-peptide antibody-positive at-risk individuals	31
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance	31
The role of IL-23 in joint disease	30
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	30
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	30
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	30
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	30
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	30
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	30
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	29
Bezoar secondary to NSAID use in a patient with inflammatory arthritis	29
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	29
Real-life efficacy of guselkumab in patients with early psoriatic arthritis	29
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	29
Annular erythematous plaques as manifestation of vasculitis in pediatric Sjögren’s syndrome	29
A case of carpal tunnel syndrome caused by gouty tophi confirmed by dual-source CT	29
The state of data sharing in rheumatology: a systematic review of top journal practices	28
Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	28
Validation of a questionnaire for central nervous system aspects of joint pain: the CAP questionnaire	28
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	28
OA44 Increasing access to rehabilitation for knee and hip osteoarthritis - ESCAPE-pain in leisure/community centres	28
The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis	27
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment	27
Identification and characteristics of patients with axial psoriatic arthritis: clinical, phenotypic, and imaging associations	27
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients	27

Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study	27
P033 The intriguing association between fibromyalgia, hypermobility and neurodivergence: a pilot study	27
Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis	27
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis	27
Comment on: Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients	27
Examination of nailfold videocapillaroscopy findings in ANCA-associated vasculitis	26
Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosis	26
E051 Audit of the management of patients over 75 with osteoporotic fragility fractures in primary care	26
Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests	26
Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiology in patients with systemic sclerosis	26
P004 Temporal and regional variation in the initiation of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study	26
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?	26
P133 Experiences of people with digital ulcers through filmed interviews	26
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	26
OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years	26
P114 Medication adherence to b/tsDMARDS remains sub-optimal in refractory rheumatoid arthritis	25
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE	25
29 Juvenile idiopathic arthritis and osteogenesis imperfecta: an exceptional association	25
OA22 Methotrexate drug monitoring and referral patterns to Hepatology - can we improve detection and monitoring of hepatoxicity with methotrexate use?	25
Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort	25
Comment on: Predictors of lack of response to methotrexate in juvenile idiopathic arthritis–associated uveitis	25
P041 Successful reversal of microvascular damage with standard therapy in a case of dermatomyositis overlap syndrome	25
Prodromal symptoms of rheumatoid arthritis in a primary care database: variation by ethnicity and socioeconomic status	25
Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica	25
Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study	25
The usefulness of ultrasound in predicting outcomes in patients with shoulder pain: a prospective observational study	24
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis	24
The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial	24
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	24
Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3	24
Negative back beliefs are associated with increased odds of low back pain and disability: a 10-year cohort study in men	24
The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership	24
Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis	24
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis	24
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib	24
An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis?	23
Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity	23
The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus	23
Type I interferon dysregulation drives distinct pathogenic pathways in early- and late-onset lupus nephritis	23
A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis	23
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort	23
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE	23
VEXAS syndrome mimicking lupus-like disease	23
Oxidative stress-induced senescence mediates inflammatory and fibrotic phenotypes in fibroblasts from systemic sclerosis patients	23
Corrigendum to: Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from EUROAPS registry	23
Gastrointestinal manifestations in systemic lupus erythematosus: data from an Indian multi-institutional inception (INSPIRE) cohort	22
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	22
P163 The cytokine horror: Kawasaki disease shock syndrome complicated with macrophage activation syndrome	22
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus	22
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study	22
Correction to: Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region	22
Correction to: TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis	22
IGFBP5 regulates fibrocartilage differentiation and cartilage injury induced by T-2 toxin via blocking IGF-1/IGF-1R signalling	22
Comparison of salivary gland MRI and ultrasonography findings among patients with Sjögren’s syndrome over a wide age range	22
P083 Primary Goujerot- Sjögren Syndrome: a pediatric case report	22
P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s Syndrome	21
OA06 Single-centre experience of the use of Rituximab for inflammatory arthritis during the COVID-19 pandemic	21
E68 Kawasaki Disease before and during COVID-19	21
P167 COVID-19 perniosis, a differential diagnosis to consider in adolescent patients presenting with chilblain-like lesions	21
OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study	21
E71 Distribution of cells and extracellular matrix in the normal marginal synovium of the hip joint capsule during the postnatal period	21
P130 Pharmacist-led osteoporosis telephone service	21
P303 Development of a Behçet’s disease specific patient concerns inventory	21
P278 Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis patients through 52 weeks: data from three phase III,	21
P212 Understandings and responses to joint pain: preliminary findings from a rapid ethnographic assessment in Northern Tanzania	21
E29 Juvenile Idiopathic Arthritis (JIA) in Algeria, from diagnosis to management	21
P293 Tocilizumab for refractory or relapsing giant cell arteritis: audit data from the Bristol and Bath regional multidisciplinary meetings 2018-2021	21
P274 The effect of ixekizumab versus adalimumab on individual components of the ACR composite score, with and without concomitant methotrexate or other conventional synthetic DMARDs, at 52 weeks in pa	21
P284 Evaluation of a self-management smartphone app for those living with Sjögren’s syndrome: a fully remote randomised pilot and feasibility trial	21
P296 Giant cell arteritis/large vessel vasculitis with normal inflammatory markers: a case series of 15 patients in south Manchester	20
P177 Investigating the neural differences in individuals with chronic widespread pain or fibromyalgia and the effect of sleep: a cross-sectional study using data from UK Biobank	20
20 Does hip involvement affect foot and ankle in juvenile idiopathic arthritis?	20
61 The nailfold videocapillaroscopy in pediatric Behçet’s disease: a multi-center study	20
P257 Are there regional variations in access to biological disease modifying anti-rheumatic drugs for the treatment of psoriatic arthritis in England?	20
P301 Patient reported outcome measure for giant cell arteritis: clinical testing	20
56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy	20
P229 Integrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis	20
P247 Novel therapeutic peptides targeting CD206 modulate ATP-induced release of inflammatory and B cell activating factors in lupus macrophages	20
64 Conical teeth? Think outside the box!	20
77 Case series of juvenile scleroderma from Nigeria	20

E044 Telephone clinic consultations in the COVID-19 era: the rates of conversion to face-to-face appointments and discharges in the post-pandemic years	19
E005 An audit of demographics, symptoms & investigations: Part of the survey of GCA in the SEHSCT during the COVID-19 pandemic	19
Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study	19
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders	19
Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles	19
P081 Is it necessary to test vitamin D prior to zoledronate or denosumab treatment?	19
P066 Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients	19
Axonal dysfunction is associated with interferon-γ levels in childhood-onset systemic lupus erythematosus: a multivoxel magnetic resonance spectroscopy study	19
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate	19
Genetic epidemiological analysis of hypouricaemia from 4993 Japanese on non-functional variants of URAT1/SLC22A12 gene	19
P208 PET-CT scanning of GCA patients: the additive role of opportunistic screening for cardiovascular disease in a high-risk population	19
P123 Biologic dose tapering: a patient perspective	19
P133 Attitudes to Technology supported Rheumatoid Arthritis care: Opportunities & Barriers for technology in RA - Key themes from Qualitative arm of Mixed-Methods Study	19
COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis	19
History of tonsillectomy is associated with glandular inflammation in Sjögren’s disease	19
P117 Remote monitoring of rheumatoid arthritis using RAPID3 to support patient-initiated follow up	18
OA28 VEXAS, a service evaluation in Rheumatology at Sheffield: “Seek, and ye shall find”	18
2-deoxy-2[18F]fluoro-D-glucose positron emission tomography–computed tomography in rheumatological diseases	18
P139 Impact of hand function impairment on daily life of patients with systemic sclerosis - a qualitative study	18
P127 A retrospective cohort study assessing outcomes and safety in patients receiving low dose vs high dose cyclophosphamide in myositis interstitial lung disease	18
P038 The importance of looking carefully for the cause(s)	18
Tofacitinib as a possible treatment for arthritis in an APDS2 patient	18
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry	18
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis	18
Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study	18
P094 Experts in lived experience: CLUSTER Champions and their successful collaboration in JIA research	18
P012 Pneumocystis jirovecii pneumonia in rheumatology patients - a single centre ten-year audit	18
P055 Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum	18
E005 Investigation into the post-diagnostic care and follow-up of patients with giant cell arteritis post-initiation of long-term glucocorticoids at University Hospitals Leicester NHS Foundation Trust	18
Is the relationship between deprivation and outcomes in rheumatoid arthritis mediated by body mass index? A longitudinal cohort study	18
P113 Cellular profiling of synovial fluid in inflammatory arthritis highlights disease-specific cell states with biological and diagnostic relevance	18
IgG4-related disease: not just a matter of IgG4	18
P039 Haemophagocytic lymphohistiocytosis secondary to invasive aspergillosis in a patient with undiagnosed SLE	18
Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study	18
P156 Type I interferon is raised across connective tissue diseases and is associated with haematological abnormalities and specific autoantibody profiles	17
P133 Anti-synthetase syndrome: an experience from a tertiary referral center	17
P046 The influence of deprivation in the outcomes of Psoriatic Arthritis within the UK - utilising Outcomes of Treatment in Psoriatic Arthritis Study Syndicate data	17
Physical activity in relation to the risk of systemic lupus erythematosus: a prospective study including 401 745 individuals	17
Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus–associated refractory cerebral vasculitis induces immune tolerance	17
P106 Feasibility Study of Methotrexate use Improvement in Rheumatoid Arthritis using Biomarker Feedback: The MIRA Trial	17
Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis	17
It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis	17
Sarcoid myopathy: an insidious diagnosis that can mimic inclusion body myositis	17
Registry based studies on pregnancy and rheumatic diseases: generating actionable evidence	17
Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down	17
E001 Pre-screen chest X-ray before starting methotrexate in autoimmune disease	17
OA01 Cluster medicine: the role of genetics for identifying shared biological pathways between rheumatoid arthritis and common comorbidities for targeting treatments	17
Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome	17
Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study	17
E048 A review of published data on reported staffing ratios for rheumatology specialist physiotherapists in rheumatology departments	17
When should we start screening for hydroxychloroquine retinopathy?	17
Corrigendum to: Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden	17
Multicentric Castleman disease presenting with frequent urination	17
HLA-C*06–defined endotype in psoriatic disease: an ever-widening landscape	17
Clock genes for joint health: if we could turn back time	17
Osteophytes’ position in subjects with DISH and right-sided aorta: verification of the ‘aortic pulsation protective effect’ theory	17
P027 Infliximab in the treatment of cerebral tuberculosis paradoxical reactions with vasculitis	17
P110 Characteristics of Difficult to treat Rheumatoid Arthritis patients in a large District Hospital in the UK	17
Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome	17
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis	17
OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications	17
Nailfold videocapillaroscopy findings correlate with lung outcomes in idiopathic inflammatory myopathies–related interstitial lung disease	17
Ixekizumab-associated disseminated tinea corporis in a patient with psoriatic arthritis and plaque psoriasis	17
Increased risk of myocarditis and arrythmias in anti-Ku-positive scleroderma–myositis overlap patients: a case series	17
Discordance in patient and physician global assessment in relapsing polychondritis	17
Predicting treatment response to methotrexate: are we closer to solving the enigma?	17
Raynaud’s phenomenon and digital ischaemia induced by ixekizumab	16
Quantitative chest imaging and prediction of mortality in rheumatoid arthritis–associated interstitial lung disease	16
Emerging targeted therapies in ANCA-associated vasculitis	16
Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy	16
Patient burden and joint inflammation during development of RA from arthralgia: is it similar in ACPA-positive and ACPA-negative disease?	16
Experience with upadacitinib in refractory polyarticular juvenile idiopathic arthritis	16
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care	16
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study	16
Upadacitinib in the treatment of Takayasu Arteritis: a case report on new perspectives on targeted immunomodulation	16
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study	16
Erratum to: Parvovirus B19 induces cellular senescence in human dermal fibroblasts: putative role in systemic sclerosis-associated fibrosis	16
Comment on: Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk: reply	16
Assessing the role of climate and the environment as co-factors for vasculitis diseases	16
Correction to: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis	16
Ultrasound subclinical synovitis in anti-CCP-positive at-risk individuals with musculoskeletal symptoms: an important and predictable stage in the rheumatoid arthritis continuum	16
Comment on: Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports	16
The SUMO components in rheumatoid arthritis	16
Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 2: plasma exchange may be useful under some circumstances	16
Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study	16
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews	16
Giant thymic cyst overclouding the diagnosis of fibrodysplasia ossificans progressiva: an inconvenient coincidence	16
Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases	16
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis	16
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study	16
Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry)	16
Teledidactic peer-tutored musculoskeletal ultrasound training for medical students—the TELMUS study	16
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease	16
Transcriptome analysis reveals key genes modulated by ALK5 inhibition in a bleomycin model of systemic sclerosis	16
Comment on: Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort	16